FreeCME

Assessing the Role of Biosimilars: What the Future Holds for Clinical Practice

Recent and upcoming patent expirations for some of the most commonly used biologic agents in gastroenterology and rheumatology have led to the development of biosimilar products—compounds that are designed to be highly similar to the original, or reference, product, but cannot be identical due to the complexities of producing biologic products. Evidence suggests that clinicians are confused about multiple aspects of biosimilars, including the underlying scientific principles, the development and regulatory pathways, how to use them in clinical practice, and how to educate patients about them.

As a rapidly evolving category of pharmaceuticals, a series of 1-hour live, virtual, evening symposia will be offered in March, April, and September 2017 for physicians and pharmacists who have interest to engage with experts in the areas of gastroenterology and rheumatology to assess and discuss the latest evidence in support of the anticipated introduction of biosimilars.

Through interactive case studies and didactic presentations, physicians and pharmacists will have an opportunity to participate with expert faculty in small-group discussions concerning the eventual introduction of biosimilars in clinical practice.

To learn more about biosimilars and how they may ultimately impact your practice and delivery of care to your patients, please register by clicking the button below in order to hear from experts about

  • Scientific and developmental principles
  • Legislative and regulatory pathways
  • Available efficacy and safety/tolerability data
  • Anticipated biosimilar approvals
  • Considerations for use in clinical practice
  • Approaches to patient education

Each module offers:

  • 1.0 AMA PRA Category 1 Credit™  for physicians, per module
  • 1.0 contact hours for pharmacists (1.0 CEUs), per module

 

 

Symposium I: Assessing Clinical Implications of Biosimilars in Rheumatology Practice

This curriculum is designed to meet the educational needs of dermatologists, gastroenterologists, internists, family medicine physicians, rheumatologists, pharmacists and other healthcare providers (physicians-in-training; nurse practitioners; physician assistants) involved and/or interested to learn about biosimilars.

 

Symposium II: Assessing Clinical Implications of Biosimilars in Adult and Pediatric IBD

This curriculum is designed to meet the educational needs of dermatologists, gastroenterologists, internists, family medicine physicians, rheumatologists, pharmacists and other healthcare providers (physicians-in-training; nurse practitioners; physician assistants) involved and/or interested to learn about biosimilars.

 

Symposium III: Biosimilar Update: Practice Implications in 2017 and Beyond

This curriculum is designed to meet the educational needs of dermatologists, gastroenterologists, internists, family medicine physicians, rheumatologists, pharmacists and other healthcare providers (physicians-in-training; nurse practitioners; physician assistants) involved and/or interested to learn about biosimilars.